Neuraminidase A controls pneumococcal recognition and fate: deficiency enhances immune sensing and intracellular survival, while treatment promotes phagocytic clearance. Abstract. Streptococcus pneumoniae (pneumococcus) is a leading cause of bacterial meningitis worldwide and is associated with cerebrovascular complications

How Streptococcus pneumoniae interacts with innate immunity matters. New open‑access research shows neuraminidase A (NanA) shapes immune sensing and phagocytic clearance in microglia and macrophages, with implications for pneumococcal meningitis.

vist.ly/4y22j

📢 Call for submissions: Cancer Vaccines – Global Advances

We invite research, reviews, clinical studies, commentaries & TrialsWatch articles on personalised and off‑the‑shelf cancer vaccines.

Submit by the end of April 2026

#callforpapers

Open‑access review explores how targeting monocyte dynamics could offer new therapeutic approaches for multiple sclerosis, with insights from experimental models highlighting monocyte plasticity and inflammation resolution.

vist.ly/4ydua

New open‑access paper outlines how the UK Vaccine Innovation Pathway is accelerating cancer vaccine trials across the NHS, boosting recruitment, streamlining delivery, and supporting equitable access.

vist.ly/4x25i

New research shows that adding CD28 signalling motifs to the CD3ζ chain boosts IL‑2 production and expansion of TCR‑engineered T cells, without reducing cytotoxicity. A promising step toward stronger TCR therapies for solid tumours.

Read here: vist.ly/4wxea

#Immunotherapy #TCells

New study shows the Systemic Immune‑Inflammation Index (SIII) is linked to survival in patients on immune checkpoint inhibitors, with lower SIII predicting better outcomes.

Read here: vist.ly/4wedi

#Immunotherapy #CancerResearch

Preclinical assessment of MAGE-A4-specific TCR-NK cells against solid tumors Abstract. T cell (Tc) receptor (TCR)-based cell therapies have shown clinical efficacy across many cancer types and represent an attractive strategy for ta

MAGE‑A4‑specific TCR‑engineered NK cells show strong, safe, off‑the‑shelf potential against solid tumours, combining targeted TCR activity with potent NK cytotoxicity.

Learn more: vist.ly/4w8u3

#Immunotherapy #CancerResearch

Call for reviewers. Become an ad hoc reviewer for the BSI journals. British Society for Immunology. Oxford University Press.

Discover benefits available when you become a peer reviewer for the @britsocimm.bsky.social journals, including a chance work with immunology experts to advance research.

🔗 oxford.ly/4sz3vPa

#ImmunoSky @ceijournal.bsky.social @imtadvances.bsky.social @discovimmunol.bsky.social

New study maps the spatial + immune landscape of metastatic dMMR colorectal cancer, revealing why some lesions respond to immunotherapy while others resist. Macrophage polarization and spatial immune architecture emerge as key drivers of outcome.

🔗 vist.ly/4v6u2

📣 Call for Papers!

CD40 turns 40: Four Decades of “Forty”-fying Immunotherapy — is open for submissions until March 2026. Share your work on CD40/CD154 biology, therapeutic targeting, and future immunotherapy innovations.

Learn more about submitting here: vist.ly/4us3h

New review by Bouvain et al. highlights how ¹⁹F MRI is transforming immune imaging, offering precise inflammation detection and theranostic potential. Exciting advances include targeted neutrophil manipulation in colitis with improved outcomes.

🔗 vist.ly/4unwr

🔬 New open‑access research shows how T‑cell signals (CD40L & IL‑4) can reduce NK‑cell ADCC against malignant B cells, revealing a resistance mechanism to anti‑CD20 therapy. Combining anti‑CD20 + anti‑NKG2A may overcome it.

Read: vist.ly/4tzga

🔬 New open‑access review explores tumour‑associated macrophages (TAMs): their role in tumour progression, metastasis, therapy resistance, and the ongoing challenge of identifying reliable TAM surface markers for immunotherapy development.

🔗 https://bit.ly/4i95qnm

🚨 Call for Papers! “CD40 turns 40: Four Decades of ‘Forty’-fying Immunotherapy.”

We invite submissions on CD40/CD154 biology & therapeutic innovation across cancer, autoimmunity, transplantation & allergy.

📝 Deadline: March 2026
📩 More info: journals@immunology.org

🧬 Spatial profiling of metastatic dMMR colorectal cancer shows why some lesions respond to PD‑1 therapy: responsive sites have strong cytotoxic/IFN‑γ activity, while resistant ones show immunosuppressive macrophage programs.

🔗 https://bit.ly/4qSV3bL

#Immunotherapy #CancerResearch

Metabolic dysregulation plays a key role in Behçet’s disease. Elevated glucose & TAG levels drive Th1 differentiation, CD8⁺ T cell activation and B cell antibody production, contributing to immune dysfunction.

Read the study: https://bit.ly/44HA2t9

📢 Special Collection CD40 turns 40: Four Decades of ‘Forty’-fying Immunotherapy🧬

Exploring 40 years of CD40/CD154 biology, therapeutics, and future directions across cancer, autoimmunity, transplantation & allergy.

Submissions open until March 2026: https://bit.ly/4rMo7lY

New in Immunotherapy Advances: CD137 aptamer–shRNA chimeras show promise for targeting intratumoral Tregs. This approach downregulates key genes like EzH2 & Nrp1 in CD137⁺ Tregs and malignant cells, offering a potential new route for tumour immunotherapy.

🔗 https://bit.ly/4ad5S3o

This #WorldCancerDay, explore how bispecific T‑cell engagers (BiTEs) could strengthen T‑cell responses against solid tumours, and the challenges still holding them back.

Read the open access review here: https://bit.ly/4291Ipg

#CancerResearch #Immunotherapy #BiTEs

This #WorldCancerDay, explore how boosting natural killer (NK) cell activity, from CAR‑NK therapies to NK‑cell engagers and checkpoint strategies, could strengthen our fight against cancer.

Read the open access review: https://bit.ly/4j8dKEW

#Immunotherapy #NKcells

🎗️ Ahead of #WorldCancerDay, check out this review by Shania Makker, Charlotte Galley & Clare L Bennett exploring how advances in immunology and mRNA platforms are reshaping the future of therapeutic cancer vaccines.

Read the article: https://bit.ly/4cefxGm

A phase 3 study by Kanegane et al. reports that 20% subcutaneous immunoglobulin (Ig20Gly) given weekly or every 2 weeks maintained stable IgG levels with a favourable safety profile in Japanese patients with PIDs.

Read the open access article: https://bit.ly/3HnCGdN

📢 Call for papers!

Immunotherapy Advances invites submissions for our Special Collection on Neuroimmunology and Immunotherapy, guest edited by Marianne Boes & Majid Ghareghanim.

Deadline: March 2026.

Submit now: https://bit.ly/45mr1m8

🚀 New in Immunotherapy Advances! Margherita Boieri et al. from Zelluna ASA report promising preclinical data on MAGE‑A4–specific TCR‑NK cells, showing potent, safe activity against solid tumors.

Read the open access article: https://bit.ly/3Z8hDBW

#Immunotherapy #CellTherapy

✨ Our 2025 must‑read articles are now live!

Explore the most‑viewed and most‑cited immunotherapy papers from the past year

Discover them here: https://bit.ly/45ELeXc

#Immunotherapy

Low MHC‑I expression remains a major barrier to effective tumour immunotherapy, especially in paediatric cancers.

This review outlines mechanisms of MHC‑I downregulation and emerging approaches to restore antigen presentation.

📄 https://bit.ly/45vtfmp

Special Collection: Neuroimmunology and immunotherapy

Support @imtadvances.bsky.social in advancing immunotherapies for neurodegenerative & CNS immune-mediated diseases.

We welcome original research, reviews, and clinical trial protocols on therapeutic development in neuroimmunology: oxford.ly/4pBKPwp

#ImmunoSky #Immunotherapy

Can blood‑based T‑cell markers predict PD‑1 therapy response in melanoma? This study suggests yes, highlighting CD8⁺ proliferation in responders and CTLA‑4⁺ Tregs in non‑responders.

Read here📄 https://bit.ly/4pw1rVL

🚀 Submit your work to the Neuroimmunology & Immunotherapy Special Collection

Covering neurodegeneration, neuroinflammation, immune checkpoints, gut–brain axis, and more.

Deadline: March 2026.

Learn more: https://bit.ly/4psT5hG

Tumour‑reactive plasma cells are emerging as powerful players in cancer immunotherapy.

This review highlights their role, the promise of neoantigen‑reactive PCs, and the challenges in epitope prediction and screening.

📄 https://bit.ly/3SVZsMC